Letao Bo

835 total citations · 1 hit paper
15 papers, 559 citations indexed

About

Letao Bo is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Letao Bo has authored 15 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Letao Bo's work include Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (3 papers) and HIV/AIDS drug development and treatment (3 papers). Letao Bo is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (3 papers) and HIV/AIDS drug development and treatment (3 papers). Letao Bo collaborates with scholars based in United States, China and Iran. Letao Bo's co-authors include Zhe‐Sheng Chen, Ruichen Wang, Hui Yang, Jiaye Wang, Leming Sun, Bowen Zhang, Weiguo Feng, Harsh Patel, Zhuo‐Xun Wu and Yidong Li and has published in prestigious journals such as SHILAP Revista de lepidopterología, Experimental Cell Research and Frontiers in Pharmacology.

In The Last Decade

Letao Bo

14 papers receiving 545 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antimicrobial peptides for combating drug-resistant bacterial infections

2023 400 citations Weiguo Feng, Jiaye Wang et al. Drug Resistance Updates profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Letao Bo United States	8	265	240	68	65	63	15	559
Alina Iulia Chiriac Germany	9	361 1.4×	259 1.1×	91 1.3×	101 1.6×	54 0.9×	9	634
Rosa Gaglione Italy	17	465 1.8×	284 1.2×	79 1.2×	82 1.3×	88 1.4×	45	729
Yuan Lyu China	16	325 1.2×	102 0.4×	42 0.6×	37 0.6×	72 1.1×	40	547
Ruichen Wang China	5	254 1.0×	236 1.0×	56 0.8×	61 0.9×	66 1.0×	6	477
Johannes F. Wentzel South Africa	14	463 1.7×	208 0.9×	30 0.4×	84 1.3×	93 1.5×	19	802
Xukai Jiang China	13	413 1.6×	185 0.8×	114 1.7×	59 0.9×	48 0.8×	42	616
Sam M. Rowe United Kingdom	10	290 1.1×	270 1.1×	52 0.8×	131 2.0×	39 0.6×	15	584
Marta Bauer Poland	16	361 1.4×	388 1.6×	41 0.6×	132 2.0×	104 1.7×	36	727
Rosa Bellavita Italy	19	442 1.7×	317 1.3×	20 0.3×	81 1.2×	67 1.1×	47	725
Anna Klöckner Germany	11	298 1.1×	158 0.7×	42 0.6×	59 0.9×	30 0.5×	17	658

Countries citing papers authored by Letao Bo

Since Specialization

Citations

This map shows the geographic impact of Letao Bo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Letao Bo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Letao Bo more than expected).

Fields of papers citing papers by Letao Bo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Letao Bo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Letao Bo. The network helps show where Letao Bo may publish in the future.

Co-authorship network of co-authors of Letao Bo

This figure shows the co-authorship network connecting the top 25 collaborators of Letao Bo. A scholar is included among the top collaborators of Letao Bo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Letao Bo. Letao Bo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Sun, Dongmei, Letao Bo, Chao Jiang, et al.. (2025). Beyond the boundary: The emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer. Drug Resistance Updates. 84. 101310–101310. 1 indexed citations

2.

Zhang, Bohan, Xiang Chen, Letao Bo, et al.. (2025). Overcoming multidrug resistance in cancer cells targeting ABC transporter ABCB1 with tyrosine kinase inhibitor: Olverembatinib. Experimental Cell Research. 455(1). 114851–114851.

3.

Yang, Huilin, Zheshen Li, Zhuo‐Xun Wu, et al.. (2025). Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206). Frontiers in Pharmacology. 16. 1606857–1606857. 1 indexed citations

4.

Bo, Letao, et al.. (2024). Combating antimicrobial resistance: the silent war. Frontiers in Pharmacology. 15. 1347750–1347750. 16 indexed citations

5.

Wang, Yanan, Joshua S. Fleishman, Bing Hao, et al.. (2024). Research progress on gene mutations and drug resistance in leukemia. Drug Resistance Updates. 79. 101195–101195. 4 indexed citations

6.

Patel, Harsh, Jiaxin Li, Letao Bo, et al.. (2024). Nanotechnology-based delivery systems to overcome drug resistance in cancer. SHILAP Revista de lepidopterología. 4(1). 5–30. 13 indexed citations

7.

Sun, Haidong, et al.. (2024). Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy. Frontiers in Pharmacology. 15. 1340764–1340764. 17 indexed citations

8.

Bo, Letao, Youyou Wang, Yidong Li, et al.. (2023). The Battlefield of Chemotherapy in Pediatric Cancers. Cancers. 15(7). 1963–1963. 16 indexed citations

9.

Feng, Weiguo, Jiaye Wang, Ruichen Wang, et al.. (2023). Antimicrobial peptides for combating drug-resistant bacterial infections. Drug Resistance Updates. 68. 100954–100954. 400 indexed citations breakdown →

10.

Xie, Yuhao, et al.. (2022). Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer. Drugs of today. 58(8). 389–398. 5 indexed citations

11.

Huang, Zoufang, et al.. (2022). The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms. Frontiers in Oncology. 12. 904637–904637. 6 indexed citations

12.

Bo, Letao, et al.. (2022). Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors. Drugs of the Future. 47(9). 661–674. 2 indexed citations

13.

Patel, Harsh, Zhuo‐Xun Wu, Yanglu Chen, Letao Bo, & Zhe‐Sheng Chen. (2021). Drug resistance: from bacteria to cancer. Molecular Biomedicine. 2(1). 26 indexed citations

14.

Wu, Zhuo‐Xun, Yuqi Yang, Leli Zeng, et al.. (2021). Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Frontiers in Oncology. 10. 624954–624954. 19 indexed citations

15.

Li, Qien, Zhaofeng Wang, Xiaochen Zhang, et al.. (2016). Putrescine protects hulless barley from damage due to UV-B stress via H2S- and H2O2-mediated signaling pathways. Plant Cell Reports. 35(5). 1155–1168. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact